U.S. markets open in 17 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8600-0.0400 (-1.03%)
At close: 04:00PM EST
3.9100 +0.05 (+1.30%)
Pre-Market: 08:30AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close3.9000
Bid0.0000 x 800
Ask0.0000 x 4000
Day's Range3.8100 - 4.0400
52 Week Range0.2700 - 17.5000
Avg. Volume487,701
Market Cap66.299M
Beta (5Y Monthly)1.26
PE Ratio (TTM)0.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ABEO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Abeona Therapeutics Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Abeona Therapeutics Reports Third Quarter 2022 Financial Results

    Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022. “The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of t

  • GlobeNewswire

    Abeona Therapeutics Announces $35 Million Private Placement Financing

    NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable for 543,933 shares of common stock, and accompanying warrants to purchase 7,609,879 shares of its common stock to a group of new and existing institutional investors in a private placement. The offering price fo

  • GlobeNewswire

    Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

    Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was observed in post-hoc analysis of EB-101 treated wounds with severe baseline pain EB-101 was well-tolerated with no serious treatment-related adverse events, consistent with past clinical experience Plans to submit Biologics License Application (BLA) to U.S.